Half-Life.

The science of optimization.

Compound

GLP-1 Receptor Agonists

Prescription peptide drug class

FDA-approved (brand drugs)Compounded versions under FDA enforcementWADA-monitored

What it is

GLP-1 receptor agonists are peptide-based molecules that mimic the gut hormone glucagon-like peptide-1, which regulates appetite and glucose handling.[1] Tirzepatide additionally acts on the GIP receptor. The approved brand drugs in this class are FDA-overseen prescription medications — a meaningfully different regulatory category from 'research use only' peptides.[1]

Regulatory status

Brand-drug formulations are FDA-approved for specified indications. After the 2025 resolutions of the semaglutide and tirzepatide shortages, the FDA wound down the temporary mass-compounding latitude and issued warnings to more than fifty compounders over the course of the year.[2] The class is currently on the WADA Monitoring Program rather than the Prohibited List.[3]

State of the evidence

Large randomized trials document weight reduction in approved indications. A notable share of the weight lost is lean tissue, which complicates naive performance interpretations. No established performance benefit in healthy, trained adults.[1]

Sources

  1. [1]FDA, 'FDA's concerns with unapproved GLP-1 drugs used for weight loss.'
  2. [2]FDA, 'FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.'
  3. [3]WADA, 'Prohibited List.'

Educational reference only. Not medical advice. No dosing or protocols are published here.

Newsletter

The science, in your inbox.

Sourced explainers on peptides and biohacking. No hype, no claims — just the research, parsed. One email a week.

Research summaries, not medical advice. Unsubscribe anytime.